EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI

Minkyu Jung, Byoung Chul Cho, Chul Ho Lee, Hyung Soon Park, Young Ae Kang, Se Kyu Kim, Joon Chang, Dae Jun Kim, Sun Young Rha, Joo Hang Kim, Ji Hyun Lee

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Results: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.

Original languageEnglish
Pages (from-to)1128-1135
Number of pages8
JournalYonsei medical journal
Volume53
Issue number6
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung Neoplasms
Single Nucleotide Polymorphism
Introns
Non-Small Cell Lung Carcinoma
erbB-1 Genes
Microsatellite Repeats
Genotype
Dinucleotide Repeats
Genetic Polymorphisms
DNA Sequence Analysis
Genetic Promoter Regions
Restriction Fragment Length Polymorphisms
Disease-Free Survival
Mutation

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Jung, Minkyu ; Cho, Byoung Chul ; Lee, Chul Ho ; Park, Hyung Soon ; Kang, Young Ae ; Kim, Se Kyu ; Chang, Joon ; Kim, Dae Jun ; Rha, Sun Young ; Kim, Joo Hang ; Lee, Ji Hyun. / EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. In: Yonsei medical journal. 2012 ; Vol. 53, No. 6. pp. 1128-1135.
@article{659b924d2e1145708099641d4f4c25c9,
title = "EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI",
abstract = "Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Results: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5{\%} vs. 27.4{\%}, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.",
author = "Minkyu Jung and Cho, {Byoung Chul} and Lee, {Chul Ho} and Park, {Hyung Soon} and Kang, {Young Ae} and Kim, {Se Kyu} and Joon Chang and Kim, {Dae Jun} and Rha, {Sun Young} and Kim, {Joo Hang} and Lee, {Ji Hyun}",
year = "2012",
month = "11",
day = "1",
doi = "10.3349/ymj.2012.53.6.1128",
language = "English",
volume = "53",
pages = "1128--1135",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. / Jung, Minkyu; Cho, Byoung Chul; Lee, Chul Ho; Park, Hyung Soon; Kang, Young Ae; Kim, Se Kyu; Chang, Joon; Kim, Dae Jun; Rha, Sun Young; Kim, Joo Hang; Lee, Ji Hyun.

In: Yonsei medical journal, Vol. 53, No. 6, 01.11.2012, p. 1128-1135.

Research output: Contribution to journalArticle

TY - JOUR

T1 - EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI

AU - Jung, Minkyu

AU - Cho, Byoung Chul

AU - Lee, Chul Ho

AU - Park, Hyung Soon

AU - Kang, Young Ae

AU - Kim, Se Kyu

AU - Chang, Joon

AU - Kim, Dae Jun

AU - Rha, Sun Young

AU - Kim, Joo Hang

AU - Lee, Ji Hyun

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Results: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.

AB - Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Results: SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.

UR - http://www.scopus.com/inward/record.url?scp=84868117908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868117908&partnerID=8YFLogxK

U2 - 10.3349/ymj.2012.53.6.1128

DO - 10.3349/ymj.2012.53.6.1128

M3 - Article

C2 - 23074112

AN - SCOPUS:84868117908

VL - 53

SP - 1128

EP - 1135

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -